---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000001"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:29:08.415318+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NovoCure reports preliminary FY2024 net revenues $605M (+19% YoY); Q4 $161M (+21%)

## Summary
- Preliminary FY2024 net revenues $605.2M (+19% YoY); Q4 $161.3M (+21% YoY).
- Active patients globally: 4,126 total on TTFields; 4,077 Optune Gio; 52 Optune Lua prescriptions for NSCLC.
- Cash, cash equivalents and short-term investments $959.9M as of Dec 31, 2024.
- FDA approved Optune Lua for metastatic NSCLC in Oct 2024; Phase 3 PANOVA-3 trial met primary endpoint in pancreatic cancer.
- FY2025 revenue growth expected to align with Optune Gio active patient growth; US prior-period claims added $8.3M in Q4.

## SEC filing metadata
- accession: 0001645113-25-000001
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000001/0001645113-25-000001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000001/nvcr-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000001
- JSON: https://secwatch.observer/filing/0001645113-25-000001.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.